stockrowViridian Therapeutics, Inc.
VRDN Healthcare Biotechnology
Viridian Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $70.8 million, up 23,359.9% from fiscal 2024.
- Revenue
- −63.5%
- EPS
- −5.00%
- Free cash flow
- −9.92%
- Total debt
- +1,064.9%
Quarter to September 2026, against a year earlier
Follow VRDN
Alert me
Viridian Therapeutics, Inc. (VRDN) Book value per share
Viridian Therapeutics, Inc.'s book value per share at the end of fiscal 2025 was 8.5×, down 13.9% from 9.9× in fiscal 2024. At the end of the quarter to 30 September 2026 it was 0.0×. Over the past ten years it has ranged from 7.5× (fiscal 2019) to 367× (fiscal 2016); the current reading is higher than 18% of that period. Viridian Therapeutics, Inc. ranks 477th of 611 Biotechnology companies by book value per share.
Book value per share, annual
Embed this chart
Annual newest first
| Period | Book value per share | Change |
|---|---|---|
| FY2025 | 8.5× | (13.93%) |
| FY2024 | 9.9× | 0.17% |
| FY2023 | 9.9× | (19.78%) |
| FY2022 | 12.3× | (21.82%) |
| FY2021 | 15.7× | (53.33%) |
| FY2020 | 33.7× | 347.49% |
| FY2019 | 7.5× | (71.00%) |
| FY2018 | 26.0× | (13.32%) |
| FY2017 | 30.0× | (91.83%) |
| FY2016 | 367× | 26.98% |
Quarterly newest first
| Period | Book value per share | Change |
|---|---|---|
| Sep 2026 | 0.0× | — |
| Jun 2026 | 6.1× | (1.37%) |
| Mar 2026 | 6.2× | (26.93%) |
| Dec 2025 | 8.5× | 38.47% |
| 43 more quarters | Free account |
Against its own ten years
Book value per share against peers
| Company | Book value per share |
|---|---|
| ELVN Enliven Therapeutics, Inc. compare | 13.5× |
| IDYA IDEAYA Biosciences, Inc. compare | 10.6× |
| VKTX Viking Therapeutics, Inc. compare | 5.0× |
| DNLI Denali Therapeutics Inc. compare | 4.9× |
| DYN Dyne Therapeutics, Inc. compare | 4.2× |
| TARS Tarsus Pharmaceuticals, Inc. compare | 2.2× |
| VRDN Viridian Therapeutics, Inc. | 0.0× |
| TLX Telix Pharmaceuticals Limited compare | 0.0× |
| CELC Celcuity, Inc. compare | −0.2× |
What Book value per share is
BV per Share tells an investor how much of a company’s accounting net worth stands behind each share.
(Shareholders Equity (Total) ÷ Shares (Basic, Weighted))
More on VRDN
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Revenue growth
- Piotroski F-score
- Altman Z-score
- The full statement